ClinicalTrials.gg
CompletedNCT03748186Updated Aug 20, 2025

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

A Phase 1 interventional study of STRO-002 in Ovarian Cancer, Ovarian Carcinoma and Ovary Cancer, sponsored by Sutro Biopharma, Inc.. Completed at 27 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-20.

Primary conditionCarcinoma, EndometrioidRegistry: Ovarian NeoplasmsReclassifiedWhy we changed it
Registry
Ovarian Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Endometrioid
Why
  1. The study's listed conditions name Carcinoma, Endometrioid, a narrower term within Ovarian Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sutro Biopharma, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Carcinoma, Endometrioid with a site in United States — 7 open to participants now, 13 under way, 1 of them phase 3. Carcinoma, Endometrioid · United States.

Enrollment
6th of 28
136 · median 79
Started
2019
with 2 others
Phase 1
6 of 32
none open now
Registered
18th of 32
by date

Among the 32 studies in Carcinoma, Endometrioid with a site in United States, this one is the 6th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2019, is one of 6 in phase 1, and was the 18th registered.

Carcinoma, Endometrioid

46 studies on the registry are indexed under Carcinoma, Endometrioid; 11 are open to participants now.

Browse Carcinoma, Endometrioid studies →

Open to participants now

7 of the 32 studies in Carcinoma, Endometrioid with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Carcinoma, Endometrioid studies recruiting now, 8 (73%) set no upper age limit and 3 (27%) stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Carcinoma, Endometrioid with a site in United States, or all of them as a file.
02

Study summary

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

Read the detailed description

This study is a phase 1, open-label, multicenter, dose-escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and to evaluate the safety, tolerability, and preliminary antitumor activity of STRO-002 in adult subjects with advanced epithelial ovarian cancer (EOC), including fallopian or primary peritoneal cancer, and endometrial cancer. Fallopian tube and primary peritoneal cancers are treated in the same manner as epithelial ovarian cancers and are thus included in this phase 1 study. Subjects enrolled in the study will be required to have progressive or recurrent disease after standard approved therapy as defined in the study eligibility criteria. The study has completed dose escalation and is currently in dose expansion, enrolling endometrial and ovarian cancer subjects.

All subjects enrolled on the study are required to have tumor tissue for determining folate receptor alpha (FolRα) expression levels, either from a prior surgery or tumor biopsy or from a biopsy performed during study screening. The testing for FolRα is done via an ICH assay. A minimum level of FolRα expression is required for enrollment for endometrial cancer but not for ovarian cancer.

Study drug, STRO-002, is administered by intravenous (IV) infusion on day 1 of 21-day cycles. Clinical evaluations and/or laboratory tests will be performed at a pre-specified schedule-weekly for cycles 1-4, and at the beginning of every cycle starting with cycle 5 as described in the schedule of assessments. Samples for PK analysis will occur at specific times on days 1, 8, and 15 of cycles 1 and 4, Day 1 of cycles 2, 3, and 5 and at the end of treatment (EOT) visit. The study requires imaging with a CT or MRI scan of the chest abdomen and pelvis at screening, every 6 weeks after enrollment for the first 18 weeks, then every 9 weeks, and at the end of treatment (EOT) visit. Additional X-rays may be required to confirm disease responses and per local institution standard of care.

Additional clinical evaluations and lab testing may occur at the discretion of the investigator.

03

Conditions studied

  • Ovarian Cancer
  • Ovarian Carcinoma
  • Ovary Cancer
  • Endometrial Cancer
  • Endometrioid Adenocarcinoma
  • Fallopian Tube Cancer
  • Primary Peritoneal Carcinoma
04

In context

Carcinoma, Endometrioid Reclassified

46 studies on the registry are indexed under Carcinoma, Endometrioid; 11 are open to participants now.

This study's enrollment of 136 is above the median of 79 across 36 interventional studies indexed under Carcinoma, Endometrioid.

Browse Carcinoma, Endometrioid studies →

Lead sponsor

Sutro Biopharma, Inc. is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Compared within Carcinoma, Endometrioid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ovarian Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. per 1.1
  3. performance status (0-1)
  4. > 3 months
  5. Pathological confirmation of disease under study (historical information, diagnosis, pathology report, etc)

    1. Expansion Cohorts A and C: High-grade serous EOC, fallopian tube cancer or primary peritoneal cancer
    2. Expansion Cohort B: diagnosed epithelial endometrial cancer (endometrioid and serous adenocarcinomas; undifferentiated carcinoma; mixed epithelial carcinoma; or adenocarcinoma NOS)
  6. and/or progressive disease

    1. Dose Expansion Cohorts A and C (Ovarian Cancer):

      • Platinum resistant and received 1-3 prior regimens or
      • Platinum sensitive and either:
      • Progressed after 2 prior lines of platinum therapy (regardless of platinum status)and received 2-3 prior regimens or
      • Progressed after 1 line of platinum therapy and 1 line of non-platinum therapy and received a total of 2-3 prior regimens if to receive second platinum regimen.
    2. Dose Expansion Cohort B (Endometrial Cancer):

      • Relapsed or progression after at least 1 platinum-based chemotherapy regimen or 1 immunotherapy-based regimen but not to exceed more than 3 prior regimens.
  7. Fresh or samples

Exclusion criteria

Exclusion Criteria:

  1. Low grade (grade 1) ovarian carcinoma, clear cell, mucinous and sarcomatous ovarian carcinomas (Cohort A).
  2. Endometrial carcinosarcomas, leiomyosarcoma and stromal sarcomas (Cohort B).
  3. Prior treatment with a FolRα-targeting ADCs or FolRα-targeting vaccines
  4. Platinum- during frontline treatment (Cohorts A and C)
  5. Greater than 3
  6. History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment
  7. Preexisting ocular disorders, clinically significant pre-exisiting ocular disorders, severe or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
  8. central nervous system or meningeal disease
  9. Concurrent participation in another therapeutic treatment trial
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    STRO-002 treatment

    Dose Escalation: STRO-002 at increasing dose levels Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg

    Drug: STRO-002

Interventions

07

What researchers measure

Primary outcomes

  1. Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)

    Incidence of adverse events (AEs) observed across STRO-002 dose levels

    Time frame: 18 months

  2. Part 1: Define the recommended phase 2 dose (RP2D) of STRO-002

    Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels

    Time frame: 18 months

  3. Part 1: Define the maximum tolerated dose (MTD) of STRO-002

    Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels

    Time frame: 18 months

  4. Part 2: Evaluate preliminary anti-tumor activity (ovarian, Fallopian and primary peritoneal cancer patients)

    Objective response rate per RECIST 1.1

    Time frame: 24 months

  5. Part 2: Evaluate preliminary anti-tumor activity (endometrial cancer patients)

    Objective response rate per RECIST 1.1

    Time frame: 24 months

Secondary outcomes

  1. Part 1: Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax)

    Measurement of maximum plasma concentration after the administration of STRO-002

    Time frame: 18 months

  2. Part 1: Characterize the PK of STRO-002 by measuring the half-life (t1/2) of STRO-002

    Measurement of terminal half-life of STRO-002 after the administration of STRO-002

    Time frame: 18 months

  3. Part 1: Characterize the PK of STRO-002 measuring the total area under the concentration versus time curve from zero to infinity (AUCinf)

    Measurement of AUC to infinity (AUCinf)

    Time frame: 18 months

  4. Part 1: Characterize the PK of STRO-002 by measuring the clearance (CL)

    Measurement of total body clearance

    Time frame: 18 months

  5. Part 1: Characterize the PK of STRO-002 by measuring the the steady state volume of distribution (Vss)

    Measurement of steady state volume of distribution

    Time frame: 18 months

  6. Part 1: Assess the formulation of anti-drug antibodies to STRO-002

    Circulating anti-drug antibodies (ADAs) formed to STRO-002

    Time frame: 18 months

  7. Part 2: Further evaluate the incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)

    Number of patients with abnormal laboratory values and/or adverse events related to STRO-002 treatment

    Time frame: 24 months

  8. Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of duration of response (DOR) in patients treated with STRO-002

    Duration of response per RECIST 1.1

    Time frame: 24 months

  9. Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of progression-free survival (PFS) in patients treated with STRO-002

    Progression-free survival per RECIST 1.1

    Time frame: 24 months

  10. Part 2: Evaluate preliminary effect of STRO-002 treatment on CA-125 levels

    Response assessment based on the Gynecologic Cancer Intergroup (GCIG) criteria

    Time frame: 24 months

  11. Part 2: Characterize the PK of STRO-002 by measuring the maximum plasma concentration (Cmax)

    Measurement of maximum plasma concentration (Cmax) after the administration of STRO-002

    Time frame: 24 months

  12. Part 2: Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC)

    Measurement of AUC to infinity (AUC inf)

    Time frame: 24 months

  13. Part 2: Characterize the PK of STRO-002 by measuring the clearance (CL)

    Measurement of total body clearance

    Time frame: 24 months

Other outcomes

  1. Part 1: Preliminary assessment of the anti-tumor activity of STRO-002

    Objective response rate per RECIST 1.1

    Time frame: 18 months

08

Study locations

27 sites
  • Arizona Oncology - Tucson
    Tucson, Arizona 85711, United States
  • UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit
    Los Angeles, California 90095, United States
  • Sutter Health- Palo Alto Medical Foundation
    San Francisco, California 94109, United States
  • Rocky Mountain Cancer Center
    Aurora, Colorado 80012, United States
  • Yale School of Medicine
    New Haven, Connecticut 06520, United States
  • Miami Cancer Institue, Baptist Health South Florida
    Miami, Florida 33176, United States
  • University of South Florida
    Tampa, Florida 33606, United States
  • Augusta Oncology
    Augusta, Georgia 30912, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Maryland Oncology Hematology
    Rockville, Maryland 20850, United States
  • Minnesota Oncology Hematology
    Minneapolis, Minnesota 55404, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Levine Cancer Institute
    Charlotte, North Carolina 28204, United States
  • University of Cincinnati Cancer Institute
    Cincinnati, Ohio 45267, United States
  • Ohio State University, James Cancer Center
    Columbus, Ohio 43210, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • Prisma Health
    Greenville, South Carolina 29605, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Cancer Care Northwest-South Spokane
    Spokane, Washington 99204, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Vall d'Hebron Institut d'Oncologia
    Barcelona, 08035, Spain
  • Clínica Universidad de Navarra -Madrid
    Madrid, 28027, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario HM Sanchinarro - CIOCC
    Madrid, 28050, Spain
09

References and documents

Publications

  • Li X, Zhou S, Abrahams CL, Krimm S, Smith J, Bajjuri K, Stephenson HT, Henningsen R, Hanson J, Heibeck TH, Calarese D, Tran C, Yin G, Stafford RL, Yam AY, Kline T, De Almeida VI, Sato AK, Lupher M, Bedard K, Hallam TJ. Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Mol Cancer Ther. 2023 Feb 1;22(2):155-167. doi: 10.1158/1535-7163.MCT-22-0322. PubMed 36459691 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Jun 2024, 64 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2018
First posted
Nov 20, 2018
StartActual
Feb 1, 2019
Primary completionActual
Jun 4, 2024
CompletionActual
Jun 4, 2024
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03748186
Lead sponsor
Sutro Biopharma, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2018
Start date
Feb 1, 2019
Primary completion
Jun 4, 2024
Completion
Jun 4, 2024
Last update
Aug 20, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luveltamab tazevibulin

Start the discussion